PEG conjugates in clinical development or use as anticancer agents: An overview

Advanced Drug Delivery Reviews

Volumn 61, Issue 13, 2009, Pages 1177-1188

  Pasut, Gianfranco ^a   Veronese, Francesco M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Anticancer; Clinical trial; PEG conjugates; PEGylation; Protein modification

Indexed keywords

ANTICANCER; CLINICAL TRIAL; PEG CONJUGATES; PEGYLATION; PROTEIN MODIFICATION;

AMINES; AMINO ACIDS; CATALYSTS; ENZYMES; MOLECULAR WEIGHT; ORGANIC ACIDS;

POLYETHYLENE GLYCOLS;

7 ETHYL 10 HYDROXYCAMPTOTHECIN; AMINO ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ASPARAGINASE; ASPARAGINASE MACROGOL; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CDP 791; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; EPITOPE; EZN 2208; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; MACROGOL; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; PEGAMOTECAN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGYLATED GRANULOCYTE COLONY STIMULATING FACTOR; PEGYLATED MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; PEPTIDE; POLYMER; PRODRUG; PROTEIN; PROTHECAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADJUVANT THERAPY; BREAST CANCER; CANCER CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STABILITY; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; HEPATITIS B; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; IMMUNOGENICITY; IN VIVO STUDY; KIDNEY CANCER; KIDNEY CLEARANCE; LARGE CELL LYMPHOMA; MELANOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; STOMACH ADENOCARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; DRUG DESIGN; DRUG STABILITY; HUMANS; NEOPLASMS; PEPTIDES; POLYETHYLENE GLYCOLS; PROTEINS;

EID: 70349988803     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.02.010     Document Type: Review

References (107)

1. WHO Mortality Database. Accessed 2004.
2. Ferlay J., Bray F., Pisani P., Parkin D.M., and GLOBOCAN. Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No.5, Version 2.0 (2002), IARC Press, Lyon 2004
3. Goh P.P., Sze D.M., and Roufogalis B.D. Molecular and cellular regulators of cancer angiogenesis. Curr Cancer Drug Targets. 7 (2007) 743-758
4. Maeda H., Fang J., Inutsuka T., and Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol. 3 (2003) 319-328
5. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release. 65 (2000) 271-284
6. Sawa T., Wu J., Akaike T., and Maeda H. Tumor-targeting chemotherapy by a xanthine oxidase-polymer conjugate that generates oxygen-free radicals in tumor tissue. Cancer Res. 60 (2000) 666-671
7. Vellard M. The enzyme as drug: application of enzymes as pharmaceuticals. Curr. Opin. Biotechnol. 14 (2003) 444-450
8. Pasut G., and Veronese F.M. Polymer-drug conjugation, recent achievements and general strategies. Prog. Polym. Sci. 32 (2007) 933-961
9. Veronese F.M., and Harris J.M. Theme issue on "Peptide and Protein Pegylation I". Adv. Drug Deliv. Rev. 54 (2002) 453-606
10. Pasut G., Canal F., Dalla Via L., Arpicco S., Veronese F.M., and Schiavon O. Antitumoral activity of peg-gemcitabine prodrugs targeted by folic acid. J Control Release. 127 (2008) 239-248
11. Schiavon O., Pasut G., Guiotto A., Moro S., Orsolini P., and Veronese F.M. PEG-Ara-C conjugates for controlled release. European J. of Medicinal Chemistry. 39 (2004) 123-133
12. Choe Y.H., Conover C.D., Wu D., Royzen M., Gervacio Y., Borowski V., Mehlig M., and Greenwald R.B. Anticancer drug delivery systems: multi-loaded N4-acyl poly(ethylene glycol) prodrugs of ara-C.: II. Efficacy in ascites and solid tumors. J. Control. Release 79 (2002) 55-70
13. Pasut G., Scaramuzza S., Schiavon O., Mendichi R., and Veronese FM. PEG-Epirubicin conjugates with high loading. J. Bioact. Compat. Polym. 20 (2005) 213-230
14. Zhao H., Lee C., Sai P., Choe Y.H., Boro M., Pendri A., Guan S., and Greenwald R.B. 20-O-acylcamptothecin derivatives: evidence for lactone stabilization. J. Org. Chem. 65 (2000) 4601-4606
15. Langer C.J. CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. Clin Lung Cancer. Suppl 2 (2004) S85-88
16. Rowinsky E.K., Rizzo J., Ochoa L., Takimoto C.H., Forouzesh B., Schwartz G., et al. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in pantients with advanced solid malignancies. J. Clin. Oncol. 21 (2003) 148-157
17. L.C. Scott, J.C. Yao, A.B. Benson 3rd, A.L. Thomas, S. Falk, R.R. Mena, J. Picus, J. Wright, M.F. Mulcahy, J.A. Ajani, T.R. Evans. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. (In press).
18. Zhao H., Rubio B., Sapra P., Wu D., Reddy P., Sai P., Martinez A., Gao Y., Lozanguiez Y., Longley C., Greenberger L.M., and Horak I.D. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers. Bioconjug. Chem. 19 (2008) 849-859
19. Sapra P., Zhao H., Mehlig M., Malaby J., Kraft P., Longley C., Greenberger L.M., and Horak I.D. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a Camptothecin-11-refractory model. Clin. Cancer Res. 14 (2008) 1888-1896
20. Guo Z., Wheler J.J., Naing A., Mani S., Goel S., Mulcahy M., Gamza F., Longley C., Buchbinder A., and Kurzrock R. Clinical pharmacokinetics (PK) of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: a phase I, first-in-human, dose-escalation study. J. Clin. Oncol. 26 (2008) May 20 suppl; abstr 2556
21. Eldon M.A., Staschen C.M., Viegas T., and Bentley M. NKTR-102, a novel PEGylated-irinotecan conjugate, results in sustained tumor growth inhibition in mouse models of human colorectal and lung tumors that is associated with increased and sustained tumor SN38 exposure (2007), AACR-NCI-EORTC International Conference, San Francisco poster C157
22. D.D. Von Hoff, G.S. Jameson, M.J. Borad, L.S. Rosen, J. Utz, M. Basche, C. Alemany, S. Dhar, L. Acosta, T. Barker, J. Walling, J.T. Hamm. First phase I trial of NKTR-102 (PEG-Irinotecan) reveals early evidence of broad anti-tumour activity in three different schedules. 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, poster # 595.
23. R. Wolff, S. Routt, R. Hartsook, J. Riggs, W. Zhang, H. Persson, R. Johnson. NKTR-105, a novel PEGylated-docetaxel demonstrates superior anti-tumor activity compared to docetaxel in human non-small cell lung and colon cancer xenografts. 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, poster # 448.
24. Greenwald R.B., Gilbert C.W., Pendri A., Conover C.D., Xia J., and Martinez A.J. Drug delivery systems: water soluble taxol 2'-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. Med. Chem. 39 (1996) 424-431
25. Beeram M., Rowinsky E.K., Hammond L.A., Patnaik A., Schwartz G.H., de Bono J.S., et al. A phase I and pharmacokinetic (PK) study of PEG-paclitaxel in patients with advanced solid tumors (2002), ASCO Annual Meeting No405
26. Ton N.C., Parker G.J., Jackson A., Mullamitha S., Buonaccorsi G.A., Roberts C., et al. Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin. Cancer Res. 13 (2007) 7113-7118
27. Eggermont A.M.M., Suciu S., MacKie R., et al., EORTC Melanoma Group. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366 (2005) 1189-1196
28. Wang Y.S., Youngster S., Grace M., Bausch J., Bordens R., and Wyss D.F. Structural and biological characterisation of pegylated recombinant interferon α-2b and its therapeutic implications. Adv. Drug Deliv. Rev. 54 (2002) 547-570
29. Bukowski R.M., Tendler C., Cutler D., Rose E., Laughlin M.M., and Statkevich P. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer. 15 (2002) 389-396
30. Michallet M., Maloisel F., Delain M., et al., PEG-Intron CML Study Group. Pegylated recombinant interferon-alpha-2b vs recombinant interferon-alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia 18 (2004) 309-315
31. Hwu W.J., Panageas K.S., Menell J.H., Lamb L.A., Aird S., Krown S.E., Williams L.J., Chapman P.B., Livingston P.O., Wolchok J.D., and Houghton A.N. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Cancer. 106 (2006) 2445-2451
32. Spieth K., Kaufmann R., Dummer R., Garbe C., Becker J.C., Hauschild A., et al. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Ann. Oncol. 19 (2008) 801-806
33. Jabbour E., Kantarjian H., Cortes J., Thomas D., Garcia-Manero G., Ferrajoli A., Faderl S., Richie M.A., Beran M., Giles F., and Verstovsek S. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer. 110 (2007) 2012-2018
34. Eggermont A.M.M., Suciu S., Santinami M., Testori A., Kruit W.H.J., Marsden J., Punt C.J.A., Salès F., Gore M., MacKie R., Kusic Z., Dummer R., Hauschild A., Musat E., Spatz A., Keilholz U., and EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372 (2008) 117-126
35. Kirkwood J.M., Ibrahim J.G., Sondak V.K., Richards J., Flaherty L.E., Ernstoff M.S., Smith T.J., Rao U., Steele M., and Blum R.H. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of Intergroup Trial E1690/S9111/C9190. J. Clin. Oncol. 18 (2000) 2444-2458
36. ®) for the treatment of hepatitis C. Adv. Drug Deliv. Rev. 54 (2002) 571-586
37. Talpaz M., Rakhit A., Rittweger K., O'Brien S., Cortes J., Fettner S., Hooftman L., and Kantarjian H. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clin. Cancer Res. 11 (2005) 6247-6255
38. Loquai C., Nashan D., Hensen P., Luger T.A., Grabbe S., Sunderkötter C., and Schiller M. Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas. Eur. J. Dermatol. 18 (2008) 29-35
39. Lipton J.H., Khoroshko N., Golenkov A., Abdulkadyrov K., Nair K., Raghunadharao D., Brummendorf T., Yoo K., Bergstrom B., and Pegasys CML Study Group. Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia. Leuk. Lymphoma 48 (2007) 497-505
40. Welte K., Gabrilove J., Bronchud M.H., Platzer E., and Morstyn G. Filgrastrim (r-metHuG-CSF): the first 10 years. Blood. 88 (1996) 1907-1929
41. Kinstler O., Molineux G., Treuheit M., Ladd D., and Gegg C. Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 54 (2002) 477-485
42. Zamboni W.C. Pharmacokinetics of pegfilgrastim. Pharmacotherapy 23 (2003) 9 S-14 S
43. Green M.D., Koelbl H., Baselga J., et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy [comment]. Ann. Oncol. 14 (2003) 29-35
44. Holmes F.A., Jones S.E., O'Shaughnessy J., et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann. Oncol. 13 (2002) 903-909
45. Grigg A., Solal-Celigny P., Hoskin P., et al. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leukemia & Lymphoma 44 (2003) 1503-1508
46. Vogel C.L., Wojtukiewicz M.Z., Carroll R.R., et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J. Clin. Oncol. 23 (2005) 1178-1184
47. Smith T.J., Khatcheressian J., Lyman G.H., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline [see comment]. J. Clin. Oncol. 24 (2006) 3187-3205
48. Lok S., Kaushansky K., Holly R.D., et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 369 (1994) 565-568
49. Guerra P.I., Acklin C., Kosky A.A., Davis J.M., Treuheit M.J., and Brems D.N. PEGylation prevents the N-terminal degradation of megakaryocyte growth and development factor. Pharm. Res. 15 (1998) 1822-1827
50. De-Boer R.H., Roskos L.K., Cheung E., et al. Pharmacokinetic analysis of Pegylated megakaryocyte growth and development factor in humans. Growth Factors. 18 (2000) 215-226
51. Ulich T.R., Castillo J.D., Cheung E., Roskos L., Young J., Molineux G., Senaldi G., Guo J., Toombs C.F., Kaufman S., Yin S., Nelson A.g., and Sheridan W.P. The prolonged hematologic effects of a single injection of PEG-rHuMGDF in normal and thrombocytopenic mice. Blood 95 (2000) 2514-2522
52. Tanaka H., Takama H., Arai Y., Azuma J., Ohno R., Ikeda Y., and Mizoguchi H. Pharmacokinetics of pegylated recombinant human megakaryocyte growth and development factor in healthy volunteers and patients with hematological disorders. Eur. J. Haematol. 73 (2004) 269-279
53. Moskowitz C.H., Hamlin P.A., Gabrilove J., Bertino J.R., Portlock C.S., Straus D.J., Gencarelli A.N., Nimer S.D., and Zelenetz A.D. Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann. Oncol. 18 (2007) 1842-1850
54. Basser R.L., O'Flaherty E., Green M., et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood. 99 (2002) 2599-2602
55. Li J., Yang C., Xia Y., et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 98 (2001) 3241-3248
56. Sherman M.R., Saifer M.G., and Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev. 60 (2008) 59-68
57. Broome J.D. Evidence that the l-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the l-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. J. Exp. Med. 118 (1963) 99-120
58. Abuchowski A., van Es T., Palczuk N.C., McCoy J.R., and Davis F.F. Treatmentof L5178Y tumor-bearing BDF1 mice with a nonimmunogenic l-glutaminase-l-asparaginase. Cancer Treat. Rep. 63 (1979) 1127-1132
59. Park Y.K., Abuchowski A., Davis S., and Davis F. Pharmacology of Escherichia coli-l-asparaginase polyethylene glycol adduct. Anticancer Res. 1 (1981) 373-376
60. Abuchowski A., Kazo G.M., Verhoest Jr. C.R., Van Es T., Kafkewitz D., Nucci M.L., Viau A.T., and Davis F.F. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem. Biophys. 7 (1984) 175-186
61. Ho D.H., Brown N.S., Yen A., Holmes R., Keating M., Abuchowski A., Newman R.A., and Krakoff I.H. Clinical pharmacology of polyethylene glycol-l-asparaginase. Drug Metab. Dispos. 14 (1986) 349-352
62. Soares A.L., Guimaraes G.M., Polakiewicz B., de Moraes Pitombo R.N., and Abrahao-Neto J. Effects of polyethylene glycol attachment on physicochemical and biological stability of E. coli l-asparaginase. Int. J. Pharm. 237 (2002) 163-170
63. Kurtzberg J. In: Gansler T. (Ed). Cancer Medicine. 5th ed (2000), Decker Inc, Canada
64. Graham M.L. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev. 55 (2003) 1293-1302
65. Narta U.K., Kanwar S.S., and Azmi W. Pharmacological and clinical evaluation of l-asparaginase in the treatment of leukemia. Crit. Rev. Oncol. Hematol. 61 (2007) 208-221
66. ®) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). The Oncologist. 12 (2007) 991-998
67. Apostolidou E., Swords R., Alvarado Y., and Giles F.J. Treatment of acute lymphoblastic leukaemia: a new era. Drugs. 67 (2007) 2153-2171
68. J.K Armstrong. The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol). In: PEGylated Protein Drugs: Basic Science and Clinical Applications. F.M. Veronese and M. J. Bossard Edrs. Birkhäuser Verlag AG (Basel, Switzerland).(In press).
69. Armstrong J.K., Hempel G., Koling S., Chan L.S., Fisher T., Meiselman H.J., and Garratty G. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer. 110 (2007) 103-111
70. Sugimura K., Ohno T., Kusuyama T., and Azuma I. High sensitivity ofhuman melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro. Melanoma Res. 2 (1992) 191-196
71. Cheng P.N., Leung Y.C., Lo W.H., Tsui S.M., and Lam K.C. Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma. Cancer Lett. 224 (2005) 67-80
72. Savoca K.V., Abuchowski A., van Es T., Davis F.F., and Palczuk N.C. Preparation of a non-immunogenic arginase by the covalent attachment of polyethylene glycol. Biochim. Biophys. Acta 578 (1979) 47-53
73. Takaku H., Takase M., Abe S., Hayashi H., and Miyazaki K. In vivo antitumor activity of arginine deiminase purified from Mycoplasma arginini. Int. J. Cancer 51 (1992) 244-249
74. Misawa S., Aoshima M., Takaku H., Matsumoto M., and Hayashi H. High level expression of Mycoplasma arginine deiminase in Escherichia coli and its efficient renaturation as an anti-tumor enzyme. J. Biotechnol. 36 (1994) 145-155
75. Gong H., Zolzer F., von Recklinghausen G., Havers W., and Schweigerer L. Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis. Leukemia. 14 (2000) 826-829
76. Ensor C.M., Holtsberg F.W., Bomalaski J.S., and Clark M.A. PEGylated argininedeiminase (ADI-SS PEG20, 000 MW) inhibits human melanomas and hepatocellularcarcinomas in vitro and in vivo. Cancer Res. 62 (2002) 5443-5450
77. Durden D.L., and Distasio J.A. Comparison of the immunosuppressive effects of asparaginases from Escherichia coli and Vibrio succinogenes. Cancer Res. 40 (1980) 1125-1129
78. Distasio J.A., Salazar A.M., Nadji M., and Durden D.L. Glutaminase-freeasparaginase from vibrio succinogenes: an antilymphoma enzyme lacking hepatotoxicity. Int. J. Cancer 30 (1982) 343-347
79. Beloussow K., Wang L., Wu J., Ann D., and Shen W.C. Recombinant arginine deiminase as a potential anti-angiogenic agent. Cancer Lett. 183 (2002) 55-162
80. Park S., Kang S.W., Shin Y.J., Chae K.Y., Park M.O., Kim M.Y., Wheatley D.N., and Min B.H. Arginine deminase: a potential inhibitor of angiogenesis and tumor growth. Br. J. Cancer 89 (2003) 907-914
81. Holtsberg F.W., Ensor C.M., Steiner M.R., Bomalaski J.S., and Clark M.A. Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. J. Control. Release. 80 (2002) 259-271
82. Izzo F., Marra P., Beneduce G., Castello G., Vallone P., De Rosa V., Cremona F., Ensor C.M., Holtsberg F.W., Bomalaski J.S., Clark M.A., Ng C., and Curley S.A. PEGylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J. Clin. Oncol. 22 (2004) 1815-1822
83. Ascierto P.A., Scala S., Castello G., Daponte A., Simeone E., Ottaiano A., et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J. Clin. Oncol. 23 (2005) 7660-7668 Erratum in: J. Clin. Oncol. 24 (2006) 4047
84. Izzo F., Montella M., Orlando A.P., Nasti G., Beneduce G., Castello G., et al. Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis. J. Gastroenterol. Hepatol. 22 (2007) 86-91
85. Wang M., Basu A., Palm T., Hua J., Youngster S., Hwang L., et al. Engineering an arginine catabolizing bioconjugate: biochemical and pharmacological characterization of pegylated derivatives of arginine deiminase from Mycoplasma arthritidis. Bioconjugate Chem. 17 (2006) 1447-1459
86. Weickmann J.L., and Fahrney D.E. Arginine deaminase from Mycoplasma arthritidis: evidence for multiple forms. J. Biol. Chem. 252 (1977) 2615-2620
87. Weickmann J.L., Himmel M.E., Squire P.G., and Fahrney D.E. Arginine deiminase from Mycoplasma arthritidis: properties of the enzyme from log phase cultures. J. Biol. Chem. 253 (1978) 6010-6015
88. Smith D.W., Ganaway R.L., and Fahrney D.E. Arginine deiminase from Mycoplasma arthritidis: structure-activity relationships among substrates and competitive inhibitors. J. Biol. Chem. 253 (1978) 6016-6020
89. Takaku H., Matsumoto M., Misawa S., and Miyazaki K. Anti-tumor activity of arginine deiminase from Mycoplasma arginini and its growth-inhibitory mechanism. Jpn. J. Cancer Res. 86 (1995) 840-846
90. Savoca K.V., Davis F.F., van Es T., McCoy J.R., and Palczuk N.C. Cancer therapy with chemically modified enzymes. II. The therapeutic effectiveness of arginase, and arginase modified by the covalent attachment of polyethylene glycol, on the taper liver tumor and the L5178Y murine leukemia. Cancer Biochem. Biophys. 7 (1984) 261-268
91. N.M. Cheng, Y.C. Leung, W.H. Lo. Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation. US patent no. 20050244398. 2005 November 3.
92. Cheng P.N., Lam T., Lam W., Tsui S., Cheng A.W., Lo W., and Leung Y. Pegylated recombinant human arginase (rhArg-peg5, 000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res. 67 (2007) 309-317
93. Hoffman R.M., and Jacobsen S.J. Reversible growth arrest in simian virus 40-transformed human fibroblasts. Proc. Natl Acad. Sci. USA 77 (1980) 7306-7310
94. Guo H., Herrera H., Groce A., and Hoffman R.M. Expression of the biochemical defect of methionine dependence in fresh patient tumors in primary histoculture. Cancer Res. 53 (1993) 2479-2483
95. Kokkinakis D.M., Von Wronski M.A., Vuong T.H., Brent T.P., and Schold Jr. S.C. Regulation of O6-methylguanine DNA methyltransferase by methionine in human tumor cells. Br. J. Cancer 75 (1997) 779-788
96. Tan Y., Xu M., Tan X., Wang X., Saikawa Y., Nagahama T., Sun X., Lenz M., and Hoffman R.M. Overexpression and large-scale production of recombinant l-methionine-alpha-deamino-gamma-mercaptomethane-lyase for novel anticancer therapy. Protein Expr. Purif. 9 (1997) 233-245
97. Tan Y., Zavala Sr. J., Xu M., Zavala Jr. J., and Hoffman R.M. Serum methionine depletion without side effects by methioninase in metastatic breast cancer patients. Anticancer Res. 16 (1996) 3937-3942
98. Tan Y., Zavala Sr. J., Han Q., Xu M., Sun X., Tan X., Magana R., Geller J., and Hoffman R.M. Recombinant methioninase infusion reduces the biochemical endpoint of serum methionine with minimal toxicity in high-stage cancer patients. Anticancer Res. 17 (1997) 3857-3860
99. Sun X., Yang Z., Li S., Tan Y., Zhang N., Wang X., Yagi S., Yoshioka T., Takimoto A., Mitsushima K., Suginaka A., Frenkel E.P., and Hoffman R.M. In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5-phosphate supplementation. Cancer Res. 63 (2003) 8377-8383
100. Tan Y., Sun X., Xu M., An Z., Tan X.-Z., Tan X.-Y., Han Q., Miljkovic D.A., Yang M., and Hoffman R.M. Polyethylene glycol conjugation of recombinant methioninase for cancer therapy. Protein Expression Purif. 12 (1998) 45-52
101. Yang Z., Sun X., Li S., Tan Y., Wang X., Zhang N., Yagi S., Takakura T., Kobayashi Y., Takimoto A., Yoshioka T., Suginaka A., Frenkel E.P., and Hoffman R.M. Circulating half-life of PEGylated recombinant methioninase holoenzyme is highly dose dependent on cofactor pyridoxal-5-phosphate. Cancer Res. 64 (2004) 5775-5778
102. Yang Z., Wang J., Yoshioka T., Li B., Lu Q., Li S., Sun X., Tan Y., Yagi S., Frenkel E.P., and Hoffman R.M. Pharmacokinetics, methionine depletion, and antigenicity of recombinant methioninase in primates. Clin. Cancer Res. 10 (2004) 2131-2138
103. Yang Z., Wang J., Lu Q., Xu J., Kobayashi Y., Takakura T., Takimoto A., Yoshioka T., Lian C., Chen C., Zhang D., Zhang Y., Li S., Sun X., Tan Y., Yagi S., Frenkel E.P., and Hoffman R.M. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates. Cancer Res. 64 (2004) 6673-6678
104. C. Unger, F. Baas, S. Wiessner, S. Steinbild, M. Medinger, J. Drevs, R. Harzmann, J. Roberts and K. Mross. Phase I dose escalating study of PEG-PGA and DON (GlutaDON): A new amino acid depleting anti cancer drug approach. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14 S (July 15 Supplement), (2004) 3175.
105. C. Unger, R. Harzmann, C. Müller, C. Witt, J. Roberts and N. Sethuraman. Phase I dose escalating study of PEG-PGA and DON: A new amino acid depleting anti cancer drug approach. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No 16 S (June 1 Supplement), (2005) 3130.
106. C. Mueller, S. Al-Batran, E. Jaeger, B. Schmidt, M. Bausch, C. Unger, N. Sethuraman. A phase IIa study of PEGylated glutaminase (PEG-PGA) plus 6-diazo-5-oxo-L-norleucine (DON) in patients with advanced refractory solid tumors. J Clin Oncol. Vol 26, No 20 S(May Supplement), (2008) 2533.
107. Ganson N.J., Kelly S.J., Scarlett E., Sundy J.S., and Hershfield M.S. Control of hyperuricemia in subjects with refractory gout, and induction of antibody agaist poly(ethylene glycl) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res. Ther. 8 (2006) R12